1. Medicines
  2. Cardiology
  3. LEQVIO® (Inclisiran)
  4. ORION trials: efficacy and safety profile

Click here for Prescribing Information

ORION trials: efficacy and safety profile

May 20, 2021
Rate this content: 
Average: 1 (19 votes)
Print

Related Content

×

Ask Speakers

×

Medical Information Request

▼ This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website: www.hpra.ie. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: [email protected] or by calling 01 2080 612.